Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2018

  • ID: 4576079
  • Report
  • 116 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 3SBio Inc
  • Akebia Therapeutics Inc
  • Bayer AG
  • Cadila Healthcare Ltd
  • FibroGen Inc
  • Japan Tobacco Inc
  • MORE
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2018, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.

Report Highlights:

This latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 13, 5, 3 and 7 respectively.

Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBio Inc
  • Akebia Therapeutics Inc
  • Bayer AG
  • Cadila Healthcare Ltd
  • FibroGen Inc
  • Japan Tobacco Inc
  • MORE
Introduction

Report Coverage

Anemia in Chronic Kidney Disease (Renal Anemia) - Overview

Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Anemia in Chronic Kidney Disease (Renal Anemia) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anemia in Chronic Kidney Disease (Renal Anemia) - Companies Involved in Therapeutics Development

3SBio Inc

Aevi Genomic Medicine Inc

Akebia Therapeutics Inc

Amgen Inc

Bayer AG

Betta Pharmaceuticals Co Ltd

Biocad

Cadila Healthcare Ltd

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

FibroGen Inc

GlaxoSmithKline Plc

Japan Tobacco Inc

JCR Pharmaceuticals Co Ltd

Panacea Biotec Ltd

Pangen Biotech Inc.

PharmaEssentia Corp

PhytoHealth Corp

Pieris Pharmaceuticals Inc

Taisho Pharmaceutical Holdings Co Ltd

Xenetic Biosciences Inc

Anemia in Chronic Kidney Disease (Renal Anemia) - Drug Profiles

BCD-131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-5014B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daprodustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

darbepoetin alfa biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

desidustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enarodustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epoetin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ErepoXen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erythropoietin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FG-2216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDGN-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molidustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-1116 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHEP-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roxadustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SFR-1882 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSS-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0463518 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UBI-852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vadadustat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects

Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products

Anemia in Chronic Kidney Disease (Renal Anemia) - Product Development Milestones

Featured News & Press Releases

May 31, 2018: Astellas and FibroGen Announce Topline Results from Double-Blind Japan Phase 3 Study for Roxadustat in Hemodialysis Chronic Kidney Disease Patients with Anemia

Apr 09, 2018: Withdrawal of Application for a Change to the Marketing Authorization for Aranesp (Darbepoetin Alfa)

Feb 12, 2018: Akebia Therapeutics Provides Update on Vadadustat Development Program

Jan 17, 2018: JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study

Jan 04, 2018: Akebia Therapeutics Announces Positive Top-Line Results from Phase 2 Study of Vadadustat in Japanese Patients with Anemia Associated with Dialysis-Dependent Chronic Kidney Disease

Nov 01, 2017: Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal Anemia

Oct 31, 2017: Astellas and FibroGen Announce Positive Top line Results from First Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease Patients with Anemia

Jul 05, 2017: Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD

May 24, 2017: Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hypo responsive to Treatment with Erythropoiesis-Stimulating Agents

Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease

Mar 28, 2017: Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease

Nov 24, 2016: GSK starts phase III programme with daprodustat for anemia associated with chronic kidney disease

Sep 26, 2016: Akebia Announces Publication Highlighting Potential Benefits of HIF Treatments for Patients with Renal Anemia

Sep 19, 2016: Akebia Announces Publication of Phase 2b Data for Vadadustat in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease

Aug 22, 2016: Akebia Announces Publication Highlighting Need for New Solutions in Treating Dialysis Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Cadila Healthcare Ltd, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pangen Biotech Inc., H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3SBio Inc
  • Aevi Genomic Medicine Inc
  • Akebia Therapeutics Inc
  • Amgen Inc
  • Bayer AG
  • Betta Pharmaceuticals Co Ltd
  • Biocad
  • Cadila Healthcare Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Dong-A Socio Holdings Co Ltd
  • FibroGen Inc
  • GlaxoSmithKline Plc
  • Japan Tobacco Inc
  • JCR Pharmaceuticals Co Ltd
  • Panacea Biotec Ltd
  • Pangen Biotech Inc.
  • PharmaEssentia Corp
  • PhytoHealth Corp
  • Pieris Pharmaceuticals Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Xenetic Biosciences Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll